0001104659-25-014772.txt : 20250218 0001104659-25-014772.hdr.sgml : 20250218 20250218161526 ACCESSION NUMBER: 0001104659-25-014772 CONFORMED SUBMISSION TYPE: SCHEDULE 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20250218 DATE AS OF CHANGE: 20250218 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Xilio Therapeutics, Inc. CENTRAL INDEX KEY: 0001840233 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 851623397 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SCHEDULE 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-92962 FILM NUMBER: 25635073 BUSINESS ADDRESS: STREET 1: 828 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-833-1027 MAIL ADDRESS: STREET 1: 828 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SCHEDULE 13G BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 SCHEDULE 13G 1 primary_doc.xml SCHEDULE 13G 0001551152 XXXXXXXX LIVE Common Stock, par value $0.0001 per share 02/11/2025 0001840233 Xilio Therapeutics, Inc. 98422T100 828 Winter Street, Suite 300 Waltham MA 02451 Rule 13d-1(c) AbbVie Inc. DE 4347826.00 0.00 4347826.00 0.00 4347826.00 N 9.0 CO Xilio Therapeutics, Inc. 828 Winter Street, Suite 300 Waltham, Massachusetts, 02451 This statement is filed on behalf of AbbVie Inc. (the "Reporting Person") The address of the Reporting Person is 1 North Waukegan Road, North Chicago, Illinois, 60064-6400. The Reporting Person is organized under the laws of the State of Delaware. Y The information contained on the cover pages to this Schedule 13G is incorporated by reference into this Item 4.The ownership information presented herein represents beneficial ownership of the Common Stock as of the date hereof based upon 43,958,074 shares of Common Stock outstanding on November 1, 2024 according to the Issuer's Quarterly Report on Form 10-Q filed on November 7, 2024 and giving effect to the issuance of 4,347,826 shares of Common Stock to the Reporting Person on February 11, 2025. 9.0% 4,347,826 0 4,347,826 0 Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. AbbVie Inc. /s/ Scott T. Reents 02/18/2025